Fatigue in people with localized colorectal cancer who do and do not receive chemotherapy: a longitudinal prospective study

Inflammation‐ and angiogenesis‐related biomarkers are correlated with cancer‐related fatigue in colorectal cancer patients: Results from the ColoCare Study

“…There are prior data on inflammatory biomarkers as risk factors for cancer‐related fatigue in a variety of cancer types such as breast, prostate cancer and, to a limited degree, colorectal cancer (Doong et al, ; Holliday et al, ; Rodrigues, Trufelli, Fonseca, Paula, & Giglio, ; Starkweather et al, ; Vardy et al, ; Xiao et al, ). With respect to colorectal cancer, a prior study ( n = 80) examined the association between biomarker levels including IL‐6 or TGF‐α and fatigue in metastatic colorectal cancer patients (Rich et al, ).…”

“…Another study in colorectal cancer and oesophageal cancer patients confirmed these results linking IL‐6 to cancer‐related fatigue ( p < 0.0001) (Wang et al, ). Vardy et al investigated the association of several inflammatory biomarkers and cancer‐related fatigue in n = 289 colorectal cancer patients (Vardy et al, ). In contrast to our study, they collected baseline blood samples post‐surgery and prior to chemotherapy.…”

“…They did not observe a consistent association between inflammation‐related biomarkers and fatigue over time in n = 289 colorectal cancer patients. (Vardy et al, ) Only a weak association was observed at 6 months with several cytokines including IL‐6 ( ρ = −0.16 to −0.20) (Vardy et al, ).…”

“…A recent study recruited n = 289 patients with localised colorectal cancer and showed similar results with increased cancer-related fatigue during chemotherapy (70% vs. 31%) (Vardy et al, 2016). Still, the biological pathways underlying fatigue-associated symptoms in cancer patients are not completely understood (Vardy et al, 2016).…”

“…Cancerrelated fatigue is affected by multiple factors including demographic, medical, psychological, behavioural and biological factors, and impacts normal functioning and quality of life of patients and cancer survivors (Bower, 2014;Filler & Saligan, 2016;LaVoy, Fagundes, & Dantzer, 2016;Saligan et al, 2015). A recent study recruited n = 289 patients with localised colorectal cancer and showed similar results with increased cancer-related fatigue during chemotherapy (70% vs. 31%) (Vardy et al, 2016). Still, the biological pathways underlying fatigue-associated symptoms in cancer patients are not completely understood (Vardy et al, 2016).…”